Search Results - Kevin Kalinsky

  • Showing 1 - 20 results of 20
Refine Results
  1. 1

    Administration of trastuzumab deruxtecan in metastatic breast cancer patients with severe hepatic impairment by Laura Sun, Gaybrielle Moore, Annalise Labatut, Jane Meisel, Kevin Kalinsky, Kristina Byers

    Published in Current Problems in Cancer: Case Reports (2024-12-01)
    Get full text
    Article


  2. 2

    356 The Effect of Regional Anesthesia on Breast Cancer Recurrence by Reema Martini, Anna Woodbury, Kevin Kalinsky, Jeffrey Switchenko, Sunil Badve, Vinita Singh

    Get full text
    Article


  3. 3

    Monitoring Metastasis and Cachexia in a Patient with Breast Cancer: A Case Study by Nikita Consul, Xiaotao Guo, Courtney Coker, Sara Lopez-Pintado, Hanina Hibshoosh, Binsheng Zhao, Kevin Kalinsky, Swarnali Acharyya

    Published in Clinical Medicine Insights: Oncology (2016-09-01)
    Get full text
    Article


  4. 4

    Tuning Immune‐Cold Tumor by Suppressing USP10/B7‐H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs by Lidan Zeng, Yueming Zhu, Xin Cui, Junlong Chi, Amad Uddin, Zhuan Zhou, Xinxin Song, Mingji Dai, Massimo Cristofanilli, Kevin Kalinsky, Yong Wan

    Published in Advanced Science (2024-10-01)
    Get full text
    Article


  5. 5

    Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology. by Emily I Chen, Katherine D Crew, Meghna Trivedi, Danielle Awad, Mathew Maurer, Kevin Kalinsky, Antonius Koller, Purvi Patel, Jenny Kim Kim, Dawn L Hershman

    Published in PLoS ONE (2015-01-01)
    Get full text
    Article


  6. 6

    Molecular differences between younger versus older ER-positive and HER2-negative breast cancers by Tao Qing, Thomas Karn, Mariya Rozenblit, Julia Foldi, Michal Marczyk, Naing Lin Shan, Kim Blenman, Uwe Holtrich, Kevin Kalinsky, Funda Meric-Bernstam, Lajos Pusztai

    Published in npj Breast Cancer (2022-11-01)
    Get full text
    Article


  7. 7

    Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer by Douglas K. Marks, Robyn D. Gartrell, Margueritta El Asmar, Shuobo Boboila, Thomas Hart, Yan Lu, Qingfei Pan, Jiyang Yu, Hanina Hibshoosh, Hanina Hibshoosh, Hua Guo, Eleni Andreopoulou, Lisa Wiechmann, Katherine Crew, Katherine Crew, Katherine Crew, Joseph Sparano, Dawn Hershman, Dawn Hershman, Dawn Hershman, Eileen Connolly, Yvonne Saenger, Yvonne Saenger, Kevin Kalinsky, Kevin Kalinsky

    Published in Frontiers in Oncology (2020-06-01)
    Get full text
    Article


  8. 8

    Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer by Sara A. Hurvitz, Aditya Bardia, Kevin Punie, Kevin Kalinsky, Lisa A. Carey, Hope S. Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M. Tolaney

    Published in npj Breast Cancer (2024-04-01)
    Get full text
    Article


  9. 9

    Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer by Sara A. Hurvitz, Aditya Bardia, Kevin Punie, Kevin Kalinsky, Lisa A. Carey, Hope S. Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M. Tolaney

    Published in npj Breast Cancer (2024-07-01)
    Get full text
    Article


  10. 10

    Spatial biomarkers of response to eribulin plus pembrolizumab in patients with metastatic triple negative breast cancer in the ENHANCE-1 trial by Yee Hoon Foong, Qi Wang, Matthew Kearney, Hortense Le, Hua Guo, Diane Chen, Michelle Garlin Politis, Courtney F. Connelly, Kevin Kalinsky, Rami S. Vanguri, Eileen P. Connolly

    Published in npj Breast Cancer (2025-07-01)
    Get full text
    Article


  11. 11

    TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgica... by Aditya Bardia, Lajos Pusztai, Kathy Albain, Eva Maria Ciruelos, Seock-Ah Im, Dawn Hershman, Kevin Kalinsky, Claudine Isaacs, Delphine Loirat, Laura Testa, Eriko Tokunaga, Jiong Wu, Hannah Dry, William Barlow, Robert Kozarski, Micah Maxwell, Nadia Harbeck, Priyanka Sharma

    Published in Therapeutic Advances in Medical Oncology (2024-04-01)
    Get full text
    Article


  12. 12

    FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer by Yifan Tai, Angela Chow, Seoyoung Han, Courtney Coker, Wanchao Ma, Yifan Gu, Valeria Estrada Navarro, Manoj Kandpal, Hanina Hibshoosh, Kevin Kalinsky, Katia Manova-Todorova, Anton Safonov, Elaine M Walsh, Mark Robson, Larry Norton, Richard Baer, Taha Merghoub, Anup K Biswas, Swarnali Acharyya

    Published in EMBO Molecular Medicine (2024-07-01)
    Get full text
    Article


  13. 13

    Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer by Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky

    Published in npj Breast Cancer (2024-06-01)
    Get full text
    Article


  14. 14

    Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer by Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky

    Published in npj Breast Cancer (2022-08-01)
    Get full text
    Article


  15. 15

    Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis by Lisa A. Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Véronique Diéras, Florence Dalenc, Jennifer R. Diamond, Christel Fontaine, Grace Wang, Hope S. Rugo, Sara A. Hurvitz, Kevin Kalinsky, Joyce O’Shaughnessy, Sibylle Loibl, Luca Gianni, Martine Piccart, Yanni Zhu, Rosemary Delaney, See Phan, Javier Cortés

    Published in npj Breast Cancer (2022-06-01)
    Get full text
    Article


  16. 16

    Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers by Yueming Zhu, Anupam Banerjee, Ping Xie, Andrey A. Ivanov, Amad Uddin, Qiao Jiao, Junlong Jack Chi, Lidan Zeng, Ji Young Lee, Yifan Xue, Xinghua Lu, Massimo Cristofanilli, William J. Gradishar, Curtis J. Henry, Theresa W. Gillespie, Manali Ajay Bhave, Kevin Kalinsky, Haian Fu, Ivet Bahar, Bin Zhang, Yong Wan

    Published in The Journal of Clinical Investigation (2024-05-01)
    Get full text
    Article


  17. 17

    MGAT1-Guided complex N-Glycans on CD73 regulate immune evasion in triple-negative breast cancer by Junlong Jack Chi, Ping Xie, Mary Hongying Cheng, Yueming Zhu, Xin Cui, Joshua Watson, Lidan Zeng, Amad Uddin, Hoang Nguyen, Lei Li, Kelley Moremen, April Reedy, Megan Wyatt, Adam Marcus, Mingji Dai, Chrystal M. Paulos, Massimo Cristofanilli, William J. Gradishar, Shaying Zhao, Kevin Kalinsky, Mine-Chie Hung, Ivet Bahar, Bin Zhang, Yong Wan

    Published in Nature Communications (2025-04-01)
    Get full text
    Article


  18. 18

    Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer by Veronica Jones, Hongwei Holly Yin, Yate-Ching Yuan, Yongzhe Wang, Sierra Min Li, Dana Aljaber, Angelica Sanchez, Christine Quinones, Dan Schmolze, Yuan Yuan, Joanne Mortimer, Lisa Yee, Laura Kruper, Tijana Jovanovic-Talisman, Jerneja Tomsic, Nancy Sanchez, Tanya Chavez, Ruth M. O’Regan, Qamar J. Khan, Melissa Davis, Kevin Kalinsky, Jane Meisel, Rick Kittles, Lorna Rodriguez-Rodriguez, Victoria Seewaldt

    Published in Scientific Reports (2025-02-01)
    Get full text
    Article


  19. 19

    The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results by Gail D. Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T. Fields, Genee Lee, Donglu Zhang, Peter S. Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M. Violet Lee, Ola Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Hamilton, Patricia LoRusso, Ian Krop, Melissa M. Schutten, Renee Commerford, Mark X. Sliwkowski, Eunpi Cho

    Published in Nature Communications (2024-01-01)
    Get full text
    Article


  20. 20

    SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer by François-Clement Bidard, Carlos Barrios, Giampaolo Bianchini, Adam M. Brufsky, Stephen Chia, Javier Cortes, Massimo Cristofanilli, Giuseppe Curigliano, Shaheenah Dawood, Peter A. Fasching, Lorenzo Gerratana, Antonio Giordano, Michail Ignatiadis, Hiroji Iwata, Wolfgang Janni, Elgene Lim, Kevin Kalinsky, Cynthia X. Ma, Erica L. Mayer, Arielle J. Medford, Jason A. Mouabbi, Joyce O’Shaughnessy, Yeon Hee Park, Javier Pascual, Pedram Razavi, Sarah Sammons, José Luis Sandoval, Luisana Sisca, Paolo Tarantino, Seth A. Wander, Gustavo Werutsky, Nicholas A. Turner

    Published in npj Breast Cancer (2026-06-01)
    Get full text
    Article


Search Tools: